Toronto Recombinant Antibody Centre (TRAC)

Hosted by the University of Toronto’s Donnelly Centre for Cellular and Biomolecular Research, the Toronto Recombinant Antibody Centre (TRAC) is a technology platform for the generation of high-quality synthetic antibodies and other proteins for research and medicine.

TRAC aims to generate a broad repertoire of high-quality, high-affinity synthetic proteins using state-of-the-art phage display technology in a high-throughput pipeline; to evaluate the potential of synthetic proteins as biological reagents, diagnostic and prognostic tools, and therapeutic candidates, in partnership with a world-class team of experts; to share antibody and biologics reagents with research experts around the world to advance knowledge of biological processes and discovery of new therapies for a wide variety of diseases.

Since its inception, the TRAC has generated thousands of therapeutic-grade antibodies against hundreds of distinct human antigens. TRAC has established a strategy for generating antibodies with sub-nanomolar affinities, which are as good or better than conventional antibodies. Antibodies produced by TRAC have been used to detect secreted and cell-surface proteins in cell biology experiments, have been validated as effective probes and modulators of cell signaling and have proven to be effective as therapeutics in animal models of cancer and infectious diseases.


The Donnelly Centre
Medical Sciences Building
University of Toronto
160 College Street
Toronto, Ontario
M5S 3E1

Areas of Expertise

Antibodies: High thoroughput, phage display-based generation of synthetic antibodies

Protein-protein interactions: large-scale analysis of peptide recognition modules & high-thoroughput generation of peptide-based binders


Product R&D

Contact Information


Published: January 24, 2022

See how Trillium can help you

Contact Us